Tag: bone mineral density

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsBone mineral density

HazardPros Announces Public Awareness Campaign for Death and Decomposition Cleanup Services in Seattle

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Sahm Capital Signs Strategic Agreement with WalaOne to Empower WalaOne Clients with Investment Services

Tag: bone mineral density

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us